Methods: Retrospective review of City of Hope pts with melanoma, renal cell carcinoma or non-small cell lung cancer on nivolumab, pembrolizumab, and/or ipilimumab from January to November 2017 and received 2 or more doses of ICI. Pt characteristics assessed: age, sex, prior chemotherapy, steroid use, and type of immunosuppression for irAE. Microbiology records were used to identify infections.
Results: Thirty-nine infectious episodes (35 bacterial, 4 viral) were identified among 111 pts. Four bacteremia (2 B. cereus, coagulase-negative staphylococcus, 1 S. aureus), 12 urinary tract (10 gram negative rods, 2 gram positive cocci), 1 intra-abdominal, 8 skin and soft tissue infections (1 S. aureus,1 Actinomyces radinge, 1 E. faecalis, and 1 E. cloacae). There were 2 probable viral pneumonias (2 rhinovirus, 2 enterovirus) and no fungal infections. Fourteen (12.6%) infections were defined as serious (requiring intravenous antimicrobials and/or hospitalization). There was no association between the specific malignancy or ICI used and risk of infection. Steroid use was significantly associated with serious infections: 12/14 (85.7%) vs. 27/95 (28.4%); p=0.0003), and no pt had received infliximab or other immunosuppressant.
Conclusion: Bacterial infections were most common, and the only risk factor associated with serious infections in our study was steroid use. Type of ICI did not impact the rate of infection.
K. Margolin, None
S. Pal, None
J. Dickter, None
J. Ito, None
R. Salgia, None
S. Dadwal, Ansun Biopharma: Investigator , Research grant .
See more of: Poster Abstract Session